Evidence map›Paper›PMID 40574830›Full record

ReviewFrontiers in immunology2025

Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review.

Xu Jing, Wang Min, Liu Xia, Li Shanshan

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xu JingDepartment of Cardiology, State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wang MinDepartment of Hematology, China-Japan Friendship Hospital, Beijing, China.
Liu XiaDepartment of Rheumatology, Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, China.
Li ShanshanDepartment of Rheumatology, Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruxolitinib is a selective JAK1/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1γ antibody, who also suffered from essential thrombocytosis related to the

Indexed as

AutoantibodiesDermatomyositisPyrazolesTranscription FactorsAdultFemaleHumansJanus Kinase 2MutationNitrilesPyrimidinesTreatment OutcomeAutoantibodiesJAK2 protein, humanJanus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinibTranscription FactorsTRIM33 protein, humananti-TIF1γ antibodydermatomyositisessential thrombocytosisJAK2 V617F mutationruxolitinib

Identifiers

PMID40574830
PMCPMC12198177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.